Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Ginkgo Bioworks Holdings (DNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: DNA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.76% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 328.47M USD | Price to earnings Ratio - | 1Y Target Price 8.6 |
Price to earnings Ratio - | 1Y Target Price 8.6 | ||
Volume (30-day avg) 1685942 | Beta 1.24 | 52 Weeks Range 5.26 - 47.60 | Updated Date 04/2/2025 |
52 Weeks Range 5.26 - 47.60 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -240.94% | Operating Margin (TTM) -214.69% |
Management Effectiveness
Return on Assets (TTM) -19.67% | Return on Equity (TTM) -60.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 234629175 | Price to Sales(TTM) 1.45 |
Enterprise Value 234629175 | Price to Sales(TTM) 1.45 | ||
Enterprise Value to Revenue 1.03 | Enterprise Value to EBITDA -1.79 | Shares Outstanding 45808500 | Shares Floating 36712127 |
Shares Outstanding 45808500 | Shares Floating 36712127 | ||
Percent Insiders 6.59 | Percent Institutions 79.82 |
Analyst Ratings
Rating 2.5 | Target Price 8.2 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 1 | Sell 3 | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Ginkgo Bioworks Holdings
Company Overview
History and Background
Ginkgo Bioworks was founded in 2008 by MIT graduates with the vision to make biology easier to engineer. It went public via SPAC in 2021.
Core Business Areas
- Cell Programming Platform: Ginkgo's core offering is its cell programming platform, which allows customers to design and program living cells for various applications.
- Biosecurity: Through its Concentric initiative, Ginkgo provides biosecurity services, including COVID-19 testing and pathogen monitoring.
- Foundry Services: Ginkgo's foundries offer infrastructure and expertise to accelerate the design, testing, and scaling of engineered organisms.
Leadership and Structure
Jason Kelly is the CEO. The company operates with a team-based structure, focusing on different application areas.
Top Products and Market Share
Key Offerings
- Engineered Microbes for Flavors & Fragrances: Ginkgo engineers microbes to produce specific flavors and fragrances. Market share data is difficult to pinpoint precisely within this specialized niche. Competitors include Amyris (AMRS), IFF (IFF), and Evolva. Revenue is bundled within broader platform services.
- Engineered Microbes for Agriculture: Ginkgo develops microbes that can improve crop yields and reduce the need for fertilizers. Market share data is emergent and variable. Competitors include Bayer (BAYRY), Corteva (CTVA) and Pivot Bio. Revenue is bundled within broader platform services.
- Biosecurity Services: COVID-19 testing and pathogen monitoring for businesses and schools. Early market leader in synthetic biology for biosecurity. Competitors include Roche (RHHBY), Abbott (ABT) and Thermo Fisher Scientific (TMO). Revenue reported separately as biosecurity revenue.
Market Dynamics
Industry Overview
The synthetic biology industry is rapidly growing, driven by advancements in genetic engineering and increasing demand for sustainable products. It is characterized by high innovation and R&D investment.
Positioning
Ginkgo Bioworks is a leading player in the synthetic biology industry, positioned as a platform provider enabling other companies to develop bio-based products. Its competitive advantage lies in its scale, automation, and data analytics capabilities.
Total Addressable Market (TAM)
TAM estimated to be hundreds of billions of dollars across various sectors. Ginkgo aims to capture a significant share by providing foundational technology and services.
Upturn SWOT Analysis
Strengths
- Leading synthetic biology platform
- Large and growing database of biological data
- Automated foundries for rapid prototyping
- Strong partnerships with industry leaders
- Pioneer and Market Leader
Weaknesses
- High operating expenses
- Reliance on customer programs for revenue
- Long development cycles for new products
- Uncertainty regarding market adoption of synthetic biology
- Complex Revenue model
Opportunities
- Expanding into new application areas (e.g., pharmaceuticals, materials)
- Increasing demand for sustainable products
- Growing interest in biosecurity solutions
- Leveraging AI and machine learning to accelerate discovery
- Improving unit economics
Threats
- Competition from other synthetic biology companies
- Regulatory hurdles for genetically modified organisms
- Negative public perception of synthetic biology
- Economic downturn affecting R&D spending
- Technological disruption
Competitors and Market Share
Key Competitors
- AMRS
- ZYME
- CRSP
- TMO
Competitive Landscape
Ginkgo has a larger platform but many competitors target niche verticals with specific solutions.
Major Acquisitions
Bayer's West Sacramento Biologics Research & Development site and internal discovery and lead optimization platform
- Year: 2022
- Acquisition Price (USD millions): 83
- Strategic Rationale: Expand capacity and capabilities in agricultural biologics.
Growth Trajectory and Initiatives
Historical Growth: Growth has been tied to onboarding new platform partners and expansion of biosecurity services.
Future Projections: Future growth is projected to come from expanding its platform services and entering new markets. Analyst estimates vary. Refer to external financial analysis for projections.
Recent Initiatives: Strategic initiatives include expanding foundry capacity, investing in new technologies, and forming partnerships with companies in various industries.
Summary
Ginkgo Bioworks is a pioneering company in synthetic biology, with a strong platform and significant growth potential. However, high operating expenses and reliance on customer programs pose challenges. The company needs to achieve profitability to achieve long-term sustainability. Successfully entering new markets and improving unit economics are crucial. Continued innovation will support its competitive position.
Similar Companies
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
ZYME
Zymeworks Inc. Common Stock
ZYME
Zymeworks Inc. Common Stock
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ginkgo Bioworks Holdings
Exchange NYSE | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-04-19 | Founder, CEO & Director Dr. Jason Kelly Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 834 | Website https://www.ginkgo.bio |
Full time employees 834 | Website https://www.ginkgo.bio | ||
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.